Oakbrook Investments LLC grew its stake in shares of Mylan (NASDAQ:MYL) by 72.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 39,600 shares of the company’s stock after buying an additional 16,600 shares during the quarter. Oakbrook Investments LLC’s holdings in Mylan were worth $1,675,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of MYL. Vanguard Group Inc. lifted its holdings in shares of Mylan by 12.0% during the second quarter. Vanguard Group Inc. now owns 32,880,790 shares of the company’s stock worth $1,276,432,000 after purchasing an additional 3,531,974 shares during the period. Pzena Investment Management LLC lifted its holdings in Mylan by 84.1% in the third quarter. Pzena Investment Management LLC now owns 22,721,384 shares of the company’s stock valued at $712,770,000 after buying an additional 10,381,697 shares during the period. State Street Corp lifted its holdings in Mylan by 1.6% in the second quarter. State Street Corp now owns 20,498,541 shares of the company’s stock valued at $795,751,000 after buying an additional 321,977 shares during the period. Greenlight Capital Inc. lifted its holdings in Mylan by 0.4% in the third quarter. Greenlight Capital Inc. now owns 10,744,307 shares of the company’s stock valued at $337,048,000 after buying an additional 42,600 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its holdings in Mylan by 7.5% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 6,922,373 shares of the company’s stock valued at $268,726,000 after buying an additional 480,500 shares during the period. 75.00% of the stock is currently owned by hedge funds and other institutional investors.
MYL has been the topic of several recent analyst reports. Zacks Investment Research lowered shares of Mylan from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Cantor Fitzgerald set a $34.00 target price on shares of Mylan and gave the company a “hold” rating in a report on Tuesday, October 31st. Guggenheim started coverage on shares of Mylan in a research note on Tuesday, December 12th. They issued a “buy” rating and a $59.00 price target for the company. Citigroup reaffirmed a “buy” rating and issued a $58.00 price target (up from $48.00) on shares of Mylan in a research note on Thursday, January 4th. Finally, Leerink Swann started coverage on shares of Mylan in a research note on Tuesday, January 2nd. They issued a “market perform” rating and a $44.00 price target for the company. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $44.65.
Shares of Mylan (NASDAQ MYL) traded up $0.03 during mid-day trading on Friday, hitting $39.28. 7,200,000 shares of the company were exchanged, compared to its average volume of 5,990,000. Mylan has a 12 month low of $29.39 and a 12 month high of $47.82. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05. The stock has a market cap of $21,070.00, a PE ratio of 23.66, a P/E/G ratio of 1.06 and a beta of 1.35.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://stocknewstimes.com/2018/02/11/oakbrook-investments-llc-increases-stake-in-mylan-myl.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.